Clinical trial
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early…
NCT05738486 · Eli Lilly and Company, Industry · Active, not recruiting
Key facts
| NCT number | NCT05738486 |
|---|---|
| Title | A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) |
| Official title | Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults With Early Symptomatic Alzheimer's Disease |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders |
| Intervention type | Drug |
| Interventions | Donanemab, Placebo, Dexamethasone |
| Enrollment | 1,175 |
| Start date | Feb 28, 2023 |
| Primary completion | May 16, 2024 |
| Completion | May 1, 2027 |
| First posted | Feb 22, 2023 |
| Last update posted | Nov 14, 2025 |
| Countries | United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: